JCO Precision Oncology Conversations
JCO PO: Article Insights: Clinical ctDNA Testing in Advanced Pediatric Solid Tumors
Jul 29, 2026 · 9 min · 8 segments
In this episode of JCO PO: Article Insights, host Jiasen He summarizes the article, "…
JCO Precision Oncology Conversations
Jul 29, 2026 · 9 min · 8 segments
In this episode of JCO PO: Article Insights, host Jiasen He summarizes the article, "…
In modern era of test treating solid tumors, we are constantly searching for reliable biomarkers to track how a cancer changes over time, whether that's catching early signs of residual disease or pinpointing targetable mutations.
A minimally invasive blood test that can isolate and sequence tiny fragments of tumor DNA floating right in the bloodstream.
It's essentially giving us a real-time window into the tumor's genetics without a need for invasive tissue biopsy.
Right now, there are only a handful of FDA-approved liquid biopsy assays on the market, and they are mostly used in adult oncology.
One of the tests is FoundationOne Liquid CDx, a comprehensive panel that scans cell-free DNA for clinically relevant mutations across hundreds of genes.
Because most FDA-approved liquid biopsies were designed with adults in mind, their utility in pediatric oncology remains a massive question mark.
They typically carry far fewer hotspot somatic mutations than adult cancers, making them much harder to detect with traditional liquid biopsy methods.
In modern era of test treating solid tumors, we are constantly searching for reliable biomarkers to track how a cancer changes over time, whether that's catching early signs of residual disease or pinpointing targetable mutations.
A minimally invasive blood test that can isolate and sequence tiny fragments of tumor DNA floating right in the bloodstream.
It's essentially giving us a real-time window into the tumor's genetics without a need for invasive tissue biopsy.
Right now, there are only a handful of FDA-approved liquid biopsy assays on the market, and they are mostly used in adult oncology.
One of the tests is FoundationOne Liquid CDx, a comprehensive panel that scans cell-free DNA for clinically relevant mutations across hundreds of genes.
Because most FDA-approved liquid biopsies were designed with adults in mind, their utility in pediatric oncology remains a massive question mark.
They typically carry far fewer hotspot somatic mutations than adult cancers, making them much harder to detect with traditional liquid biopsy methods.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
